EG BioMed was honored to sponsor and participate in PurpleStride 2025, hosted by the Pancreatic Cancer Action Network (PanCAN) on April 26, 2025. The event served as a powerful platform to raise awareness about pancreatic cancer and promote innovation in early detection.
The event gathered pancreatic cancer patients, families, clinicians, researchers, and supporters from across the country, all united in raising awareness and inspiring hope.
Funds raised through PurpleStride support PanCAN’s core initiatives, including patient support services, the advancement of molecular testing and precision treatments, and research into early detection and innovative therapies.
EG BioMed Advances ctDNA Blood Testing—A New Hope for Early Pancreatic Cancer Detection
As one of the event sponsors, EG BioMed was honored to take part in this meaningful initiative, showcasing our innovations and core mission in the field of early cancer detection.
Pancreatic cancer is notoriously difficult to diagnose and treat due to its subtle early symptoms. To address this challenge, EG BioMed has developed the EG-Pancreatic Blood Test, a non-invasive diagnostic solution based on circulating tumor DNA (ctDNA) technology, offering a promising new option for early screening.
This technology is protected by multiple international patents and certifications, enabling earlier clinical intervention and providing reliable early risk assessment for high-risk populations.
At the PurpleStride event, we proudly showcased our innovative testing solution while engaging the community with branded giveaways—including soft purple teddy bear towels and educational brochures—to highlight our commitment to early detection and reflect our signature purple identity.
EG BioMed will continue to drive innovation in cancer diagnostics, helping patients gain earlier access to treatment and new hope. We’re committed to supporting public health initiatives that raise awareness and make a real difference in the lives of those affected by cancer.
Take the First Step Toward Proactive Pancreatic Health
As we continue expanding our footprint in the U.S., EG BioMed is partnering with trusted local healthcare providers to make our pancreatic cancer blood test more accessible. The service is currently offered at clinics such as Myrostar Health Direct Primary Care and Professional Medical Corporation, and will soon expand to additional partner locations.
- Book Your Test Appointment:
Myrostar Health Direct Primary Care- 1515 116th Ave N Ste 101, Bellevue, WA 98004
- Phone：(206) 687-1558
- Email：hello@myrostar.com
- Blood Draw:
On the day of your test, the clinic team will collect your sample and ensure secure delivery to our certified lab. - DNA Methylation Analysis:
Using advanced automated qPCR systems, we analyze your sample for cancer-related methylation patterns—ensuring accurate and timely results. - Results & Consultation:
Once your results are ready, the doctor at the clinic will explain the findings and provide personalized guidance.
Disclaimer:
The technology for the pancreatic cancer blood test has been exclusively licensed to YD Biopharma, which holds full rights for its commercial development, marketing, and distribution. YD Biopharma is committed to delivering high-quality service in the U.S. market. If you are considered high risk for pancreatic cancer, we encourage you to schedule a consultation with Myrostar Health to determine if this test is appropriate for you.
Want to learn more? Visit our official website based on your location:
U.S.: https://pse.is/7glh37
Taiwan: https://pse.is/7glgze
Contact Us:
Ruokai Lin
ruokailin@eg-bio.com